Your browser doesn't support javascript.
loading
The anterior saphenous vein. Part 3. Systematic review of the literature and payor coverage policies. Endorsed by the American Vein and Lymphatic Society, the American Venous Forum and the International Union of Phlebology.
Drgastin, Rachel; Boyle, Edward M; Labropoulos, Nicos; Caggiati, Alberto; Gasparis, Antonios; Doganci, Suat; Meissner, Mark.
Afiliação
  • Drgastin R; Inovia Vein Specialty Centers, Bend, OR, USA.
  • Boyle EM; Inovia Vein Specialty Centers, Bend, OR, USA.
  • Labropoulos N; Division of Vascular Surgery, Department of Surgery, Stony Brook Medicine, Stony Brook, NY, USA.
  • Caggiati A; Department of Anatomy, University "La Sapienza,", Rome, Italy.
  • Gasparis A; Division of Vascular Surgery, Department of Surgery, Stony Brook Medicine, Stony Brook, NY, USA.
  • Doganci S; Department of Cardiovascular Surgery, Gulhane School of Medicine, Health Sciences University, Ankara, Turkey.
  • Meissner M; Division of Vascular Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, USA.
Phlebology ; 39(5): 325-332, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38526968
ABSTRACT

OBJECTIVE:

The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage.

METHODS:

A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.

RESULTS:

Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.

CONCLUSIONS:

Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Safena / Varizes Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Safena / Varizes Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article